Syphilis Is Rising in the U.S. Here ’ s What to Know About the Sexually Transmitted Infection
Sexually transmitted infections are rising in the U.S.—particularly syphilis, which increased by 26% from 2020 to 2021, according to preliminary data from the U.S. Centers for Disease Control and Prevention (CDC) published in September. Especially troubling is a 24% rise during that time period of congenital syphilis, which infects fetuses in the womb and can cause birth defects in or even kill infants.
Fortunately, syphilis can be easily treated and cured. However, people who are infected don’t necessarily know it—and without detection and treatment, the disease can have devastating consequences.
[time-b...
Source: TIME: Health - September 27, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Disease healthscienceclimate Source Type: news
Psoriasis, PsA Insurance Coverage Remains Restrictive Psoriasis, PsA Insurance Coverage Remains Restrictive
A database review showed restrictive coverage of specialty medications for psoriatic disease beyond the label indications.MDedge News (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - September 27, 2022 Category: Nursing Tags: Rheumatology News Source Type: news
Psoriasis Drug May Have Some Cardiometabolic Benefits Psoriasis Drug May Have Some Cardiometabolic Benefits
Nonrandomized trial shows 5%-6% reduction in both visceral and subcutaneous fat, but no effect on aortic vascular inflammation.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2022 Category: Cardiology Tags: Dermatology News Source Type: news
Inflammatory Bowel Disease, Psoriasis May Be Causally Related
THURSDAY, Sept. 22, 2022 -- Inflammatory bowel disease (IBD) appears to have a causal impact on psoriasis, especially psoriatic arthritis (PsA), and total psoriasis and PsA are associated with Crohn disease (CD), according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 22, 2022 Category: Pharmaceuticals Source Type: news
Psoriasis Patients Find Psoriatic Arthritis Screening Worthwhile
TUESDAY, Sept. 20, 2022 -- Psoriatic arthritis (PsA) screening is acceptable to patients with psoriasis whether they are diagnosed with PsA or not, according to a research letter published online Aug. 17 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news
Brodalumab Suicide Risk Similar to Other Biologics, Study Finds Brodalumab Suicide Risk Similar to Other Biologics, Study Finds
Researchers evaluated data on the number of completed suicides for brodalumab and 10 other biologics approved for psoriasis from the FDA ' s Adverse Events Reporting System through the end of 2021.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 19, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
Apremilast Alleviates Severe Psoriasis in Some Children, Data Show Apremilast Alleviates Severe Psoriasis in Some Children, Data Show
Proportionally more children treated with apremilast than with placebo achieved a Physician ' s Global Assessment response at week 16, with no new safety concerns highlighted.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 19, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
Sustained Response at 2 Years Reported for Deucravacitinib Sustained Response at 2 Years Reported for Deucravacitinib
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, was approved September 9 by the FDA for treating adults with moderate to severe plaque psoriasis.MDedge News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - September 15, 2022 Category: Rheumatology Tags: Dermatology News Source Type: news
Lupus, Psoriasis Patients May Face Greater Dangers After Heart Attack
THURSDAY, Sept. 15, 2022 -- People with autoimmune disorders like lupus, rheumatoid arthritis or psoriasis who suffer a heart attack are more likely to die or develop severe heart-related complications in the aftermath, a new study shows.
A heart... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 15, 2022 Category: General Medicine Source Type: news
Causal Effect ID'd for IBD With Psoriasis, Psoriatic Arthritis
WEDNESDAY, Sept. 14, 2022 -- There seems to be a causal effect between inflammatory bowel disease and psoriasis and psoriatic arthritis, according to a study published online Sept. 14 in JAMA Dermatology.
Dennis Freuer, Ph.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2022 Category: Pharmaceuticals Source Type: news
Bain, others invest in Nimbus Therapeutics' $125M round. Here's what the CEO had to say.
Nimbus Therapeutics last made headlines in 2016, when the Cambridge-based company sold a drug for the liver disease NASH to Gilead Sciences (Nasdaq: GILD) for a clean $1.2 billion — including $400 million up front. Since then, the company has quietly shifted its focus to autoimmune disease drugs, targeting the skin disorder psoriasis and certain cancers. Nimbus got a boost to those efforts on Monday. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 12, 2022 Category: American Health Authors: Rowan Walrath Source Type: news
FDA Approves Oral TYK2 Inhibitor for Treating Psoriasis FDA Approves Oral TYK2 Inhibitor for Treating Psoriasis
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first drug in this class to be approved.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 12, 2022 Category: Dermatology Tags: Dermatology News Alert Source Type: news
First TYK2 Inhibitor for Psoriasis Wins FDA Approval
(MedPage Today) -- The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced.
The indication limits use to adults who are candidates... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 11, 2022 Category: American Health Source Type: news
Differentiating Axial Disease in PsA Versus AS With Psoriasis Differentiating Axial Disease in PsA Versus AS With Psoriasis
Some identifiers of patients with isolated axial psoriatic arthritis were older age at diagnosis, psoriatic nail lesions, and absence of inflammatory back pain.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 9, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 9, 2022 Category: Drugs & Pharmacology Source Type: news
